The researchers found that the improvement in symptom scores was greater with doxylamine-pyridoxine versus placebo (0.73 points; 95% confidence interval, 0.21 to 1.25) when the last observation carried forward imputation was used for missing data.
The researchers found that over a 12-week period there was a significant reduction in stoma-related cost of care with use of the ceramide-infused barrier, resulting in a 14% relative decrease in cost.
Mr. C, a 30-year-old male with Crohn's disease, presented to his clinician with symptoms of fatigue, lethargy, headaches, pallor, hair loss, irritability, and weakness.
Those treated with accelerated (AI) versus standard infliximab induction strategies had a numerically higher colectomy rate; however, AI treatment was correlated with more severe biochemical disease.
Among participants ≤45 years in the H. pylori-positive group, the prevalence of gallstones was lower than in the H. pylori-negative group (odds ratio, 0.653).
Results showed that disease activity scores before and after switching were not statistically significantly different (Crohn's disease activity index: P=.5657 and Truelove-Witts disease activity index: P=.7609).
The researchers found that PIE and sodium phosphate were superior to PEG, with both receiving a score of 4 on a 5-point scale (blind assessment), versus a 3 for PEG (P<0.01).
The designation is based on a review of Phase 1b clinical data which showed potential for SER-287 as a novel treatment modality for patients with UC
Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions).
The subgroup that was most frequently tested was young Caucasian men, with 61% of respondents stating that they would implement serologic testing in this group.
Clenpiq will become the only FDA-approved colonoscopy prep that is 'ready-to-drink'. The solution is cranberry-flavored and the Company says it is expected to be available in Q1 of 2018.
The researchers found that prevention of recurrent CDI after a single treatment was achieved by 96.2% of participants in the capsule and colonoscopy groups in the per-protocol analysis (difference, 0%), meeting the criterion for noninferiority.
Diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older.
Of 100 participants, 32% had EPI (faecal elastase-1 <200 μg/g) and 20% severe EPI (faecal elastase-1 <100 μg/g).
Untreated celiac disease was also associated with EPI in 4% to 80% of cases but was resolved when patients adopted a gluten-free diet.
The approval of Cinvanti was supported by Phase 2 bioequivalence data of Cinvanti and Emend IV (fosaprepitant dimeglumine; Merck), where patients treated with Cinvanti experienced fewer adverse events vs. patients treated with Emend IV, including substantially fewer infusion-site reactions.
Dose-dependent serious cardiac arrhythmias may be observed with higher dosages of ondansetron in those patients with certain pre-existing cardiac conditions.
Results showed that PPI use correlated with elevated risk of GC (hazard ratio, 2.44; 95% confidence interval, 1.42 to 4.2), while histamine-2 receptor antagonist use was not associated with increased risk (hazard ratio, 0.72; 95% confidence interval, 0.48 to 1.07).
Researchers compared patients who were prescribed aspirin over a long period (for at least six months, average duration of aspirin prescribed was 7.7 years) with non-aspirin users and assessed the incidences of a number of cancers.
In Phase 3 clinical trials involving patients with travelers' diarrhea, Aemcolo was found to be superior to placebo (P=0.0008) and non-inferior to ciprofloxacin.
The number of reactions before diagnosis was four on average. The main symptoms at the debut were vomiting and vomiting with diarrhea (97.5 and 30%, respectively), which occurred in a mean time of 126.3 minutes after ingestion of the culprit fish.
Antiemetic treatment chart including drug formulations, strengths, and usual doses for nausea/vomiting.
Varubi, a highly selective and competitive antagonist of human substance P/neurokinin (NK-1) receptor, is already available as 90mg strength tablets.